Abstract: A repair, conversion or retrofit kit includes at least two continuously closable replacement baler belts which correspond substantially in their combined width to the width of a continuously closed baler belt to be replaced. The replacement baler belts may be closable in a force-fitting and/or form-fitting manner by a connecting means, and the connecting means may be at least partially hook connectors. In some embodiments, the repair, conversion or retrofit kit further includes at least one guide means arranged on the round baler such that at least two replacement baler belts each extend laterally with respect to the at least one guide means, and the at least two replacement baler belts are guided laterally with respect to one another. In some cases, the guide means is an auxiliary guide disk arranged on a rotatable shaft of the round baler.

Abstract: A belt, such as a round baler belt, includes an internal region, an external region, a core region arranged between the internal region and the external region, and at least one peripheral region arranged transversely to longitudinal direction of the round baler belt. The peripheral region is arranged at least partially between the internal region and the external region, and the belt is continuously closed in the longitudinal direction. The peripheral region may be arranged entirely between the internal region and the external region. In some cases, at least one peripheral region is two peripheral regions located opposite one another transversely to the longitudinal direction. Furthermore, the core region may be continuously wound, and even formed of reinforcing fabric. In some aspects, the internal region and/or the external region and/or a peripheral region and/or both peripheral regions contain an elastomeric material.

Abstract: The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.

Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.

Abstract: Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins.

Abstract: The present invention relates to FVIII conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia.

Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.

Abstract: The present invention relates to modified therapeutic proteins, such as e.g. coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group.

Abstract: The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.

Abstract: The present invention relates to FVIII conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia.

Abstract: The present invention relates to Factor IX polypeptides conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used—for example—in the treatment or prevention of bleeding disorders such as haemophilia B.

Abstract: The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers.

Abstract: A rubber continuous annular baler press belt is made of at least one of rubber and rubber-like materials. The press belt includes an embedded core of a reinforcing fabric and has at least two individual superimposed fabric layers (6, 7, 8). The ends of each fabric layer mutually abut and do not overlap each other at the abutment location. The abutment locations (11, 13, 15) are arranged over the periphery of the press belt so as to be offset from each other.

Abstract: The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof.

Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Abstract: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.

Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.

Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.

Abstract: An annular baler for agricultural use includes at least one annular baler belt made of rubber or rubber-like materials with an embedded core defining a reinforcement. The annular baler belt has ventilation bores which are distributed in a regular or irregular pattern around the periphery thereof and extend through the annular baler belt.

Abstract: An annular baler for agricultural use including at least one annular baler belt made of rubber or rubber-like materials with an embedded core defining a reinforcement. The annular baler belt has ventilation bores which are distributed in a regular or irregular pattern around the periphery thereof and extend through the annular baler belt.